Analysts expect Heat Biologics Inc (NASDAQ:HTBX) to report $3.32 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Heat Biologics’ earnings. The lowest sales estimate is $1.20 million and the highest is $6.95 million. Heat Biologics posted sales of $470,000.00 during the same quarter last year, which would suggest a positive year over year growth rate of 606.4%. The business is expected to report its next earnings results on Monday, November 12th.
According to Zacks, analysts expect that Heat Biologics will report full year sales of $6.28 million for the current year, with estimates ranging from $4.30 million to $8.40 million. For the next financial year, analysts anticipate that the firm will report sales of $3.23 million per share, with estimates ranging from $2.40 million to $4.80 million. Zacks’ sales calculations are an average based on a survey of research firms that cover Heat Biologics.
Heat Biologics (NASDAQ:HTBX) last issued its quarterly earnings results on Tuesday, August 14th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.09). Heat Biologics had a negative return on equity of 116.28% and a negative net margin of 437.62%. The business had revenue of $1.14 million during the quarter, compared to the consensus estimate of $1.11 million.
HTBX has been the topic of several research reports. Eurobank EFG initiated coverage on shares of Heat Biologics in a research report on Monday, July 9th. They issued a “buy” rating and a $11.00 price target on the stock. HC Wainwright initiated coverage on shares of Heat Biologics in a research report on Tuesday, June 26th. They issued a “buy” rating and a $6.00 price target on the stock. Finally, Brookline Cap M reiterated a “buy” rating on shares of Heat Biologics in a research report on Wednesday, August 1st.
Heat Biologics stock traded down $0.03 during midday trading on Thursday, hitting $1.87. The company’s stock had a trading volume of 113,033 shares, compared to its average volume of 232,850. Heat Biologics has a 12 month low of $1.09 and a 12 month high of $7.90.
About Heat Biologics
Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.
See Also: Discover Your Risk Tolerance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.